Claus Kremoser - Max-Planck-Institute for Developmental Biology Department of Physical Biology 72076 Tübingen, Federal Republic of Germany

基本信息

Career Trajectory

Bio

At WMT we are now focussing on new targets that can be addressed by small molecules. We pursue two targets that have can stimulate the immune system in an otherwise cancer permissive tumour environment. Details soon to come...

Research Interests

Papers共 73 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Development of Cilofexor, an Intestinally-Biased Farnesoid X Receptor Agonist, for the Treatment of Fatty Liver Disease

David Hollenback,Eva Hambruch,Gero Fink,Manfred Birkel,Andreas Schulz,Martin Hornberger,Kathy Liu, Kelly MacLennan Staiger,Helen Desiree Krol,Ulrich Deuschle,Christoph Steeneck,Olaf Kinzel,John T. Liles,Grant Budas,William J. Watkins,Claus Kremoser

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICSno. 1 (2024): 61-75

Cited0Views0WOSBibtex

Tlc-2716, a potent, liver-targeted, inverse agonist of the liver x receptor (lxr), demonstrates profound reductions in hepatic and plasma lipids in dysmetabolic rodent models

Archana Vijayakumar,Eisuke Murakami,Claus Kremoser, Jen-hieh Chuang,Steve Weng,Ryan S. Huss,G. Mani Subramanian,Robert P. Myers

HEPATOLOGY（2022）

Cited0Views0Bibtex

FXR Agonists for NASH: How Are They Different and What Difference Do They Make

Claus Kremoser

Journal of Hepatology（2021）

Cited48Views0WOSBibtex

Free deoxycholic acid exacerbates vascular calcification in chronic kidney disease through ER stress-mediated ATF4 activation

Shinobu Miyazaki-Anzai,Masashi Masuda,Yuji Shiozaki,Audrey L. Keenan,Michel Chonchol,Claus Kremoser,Makoto Miyazaki

Kidney (2021)

Cited9Views0Bibtex

The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model

Philipp Schwabl,Eva Hambruch,Grant R. Budas,Paul Supper,Michael Burnet,John T. Liles,Manfred Birkel,Ksenia Brusilovskaya,Philipp Konigshofer,Markus Peck-Radosavljevic,William J. Watkins,Michael Trauner,David G. Breckenridge,Claus Kremoser,Thomas Reiberger

Biomedicinesno. 1 (2021): 60-60

Cited48Views0WOSBibtex

Free Deoxycholic Acid Exacerbates Vascular Calcification in CKD Through ER Stress-Mediated ATF4 Activation

Shinobu Miyazaki-Anzai,Masashi Masuda,Yuji Shiozaki,Audrey L. Keenan,Michel Chonchol,Claus Kremoser,Makoto Miyazaki

Kidney360no. 5 (2021): 857-868

Cited7Views0WOSBibtex

Nonsteroidal FXR Ligands: Current Status and Clinical Applications

Christian Gege,Eva Hambruch,Nina Hambruch,Olaf Kinzel,Claus Kremoser

Handb Exp Pharmacol（2019）

Cited71Views0WOSBibtex

How To Develop A Differentiated Fxr Agonist: Gs-9674 Shows A Reduced Side Effect Profile In Mice, Monkeys Amd Human Phase I Studies Compared To Its Predecessor Px-102

Eva Hambruch,David Hollenback,John Liles,Olaf Kinzel,Manfred Birkel,Gero Fink,Dorothy French,Christian Gege,Martin Hornberger,William Watkins,Claus Kremoser

JOURNAL OF HEPATOLOGY（2019）

Cited2Views0Bibtex

Identification of a Potent, Orally Bioavailable and Selective MCT4 Inhibitor for the Treatment of Solid Warburg Tumors

Nina Hambruch,Barbara Herkert,Christian Gege,Aurelie Mallinger, Johannes Fabian,Olaf Kinzel,Yansong Wang,Gero Fink,Michael Albers, Anette Funk, Annika Bittman-Waetzig, Tilly Fleckenstein,Floriane Braun,Claus Kremoser

CANCER RESEARCH（2019）

Cited2Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn